CD99在血液肿瘤免疫治疗中的研究进展  

Current progress of CD99 in immunotherapy of hematological malignancies

作　　者：张经萍(综述) 文瑞婷 杨志刚(审校) ZHANG Jing-ping;WEN Rui-ting;YANG Zhi-gang(Department of Hematopathology,Zhanjiang Central Hospital Affiliated to Guangdong Medical University,Zhanjiang 524000,Guangdong,CHINA)

机构地区：[1]广东医科大学附属湛江中心医院血液内科,广东湛江524000

出　　处：《海南医学》2022年第23期3118-3120,共3页Hainan Medical Journal

基　　金：广东省自然科学基金(编号:2021A1515010708);广东省湛江市财政资金科技专项竞争性分配项目(编号:2021A05153、2020A0611、2020A06001)。

摘　　要：研究发现,CD99参与了恶性造血,在髓系和淋巴系造血细胞表面均有明显表达,并且与疾病预后不良相关。不同亚型的CD99在细胞环境中发挥不同的作用,其在血液系统恶性肿瘤中的作用存在一些差异。目前,以CD99为靶点的单克隆抗体以及嵌合型抗原受体T细胞(CAR-T)治疗被认为是血液肿瘤非常有前景的免疫治疗策略。因此,本文就CD99的结构与功能及其在血液肿瘤免疫治疗中的研究进展做一综述。Studies have found that CD99 is involved in malignant hematopoiesis and is significantly expressed on the surface of myeloid and lymphoid hematopoietic cells,which is related to poor prognosis of diseases.Different subtypes of CD99 function differentially in the cellular microenvironment,resulting distinct effects in hematological malignancies.At present,immunotherapies targeting CD99 through monoclonal antibodies or chimeric antigen receptor T cells(CAR T)are considered to be promising strategies for treatment of hematologic malignancies.Therefore,this paper reviews the structure and function of CD99 and its research progress in the immunotherapy of hematological tumors.

关 键 词：CD99 血液肿瘤 免疫治疗 预后标记 单克隆抗体 

分 类 号：R733.7[医药卫生—肿瘤]